{"id":"psychotropic-medication-optimization","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is not a single drug entity but rather a therapeutic approach or clinical program, typically involving pharmacogenomic testing, dose adjustment, and medication selection optimization for patients on psychotropic agents. It aims to personalize treatment by matching medications to individual patient factors including genetics, comorbidities, and prior response history.","oneSentence":"Psychotropic medication optimization is a clinical service/program that systematically adjusts psychiatric medications to improve efficacy and tolerability for individual patients.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:36:48.677Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Optimization of antidepressant, antipsychotic, and mood stabilizer therapy in patients with treatment-resistant or suboptimal response to psychotropic medications"}]},"trialDetails":[{"nctId":"NCT02493868","phase":"PHASE3","title":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-01","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":719},{"nctId":"NCT02497287","phase":"PHASE3","title":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-30","conditions":"Treatment-resistant Depression","enrollment":802},{"nctId":"NCT04771364","phase":"","title":"Impact of \"ASAP\" Multidisciplinary Optimization Care Protocol on Clinical Outcome in Elderly Inpatients for Hip Fracture","status":"COMPLETED","sponsor":"University of Liege","startDate":"2017-01-01","conditions":"Hip Fractures","enrollment":800},{"nctId":"NCT04985305","phase":"NA","title":"Optimization of Deprescribing Antidepressants in Nursing Home Residents With Dementia","status":"COMPLETED","sponsor":"University of Copenhagen","startDate":"2021-10-15","conditions":"Dementia, Deprescriptions, Antidepressive Agents","enrollment":180},{"nctId":"NCT00347269","phase":"PHASE4","title":"Primary Care Intervention Strategy for Anxiety Disorders","status":"COMPLETED","sponsor":"University of Washington","startDate":"2006-06","conditions":"Post-traumatic Stress Disorder, Generalized Anxiety Disorder, Panic Disorder","enrollment":1004}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SSRI, SNRI, Benzodiazepine,"],"phase":"marketed","status":"active","brandName":"Psychotropic medication optimization","genericName":"Psychotropic medication optimization","companyName":"University of Washington","companyId":"university-of-washington","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Psychotropic medication optimization is a clinical service/program that systematically adjusts psychiatric medications to improve efficacy and tolerability for individual patients. Used for Optimization of antidepressant, antipsychotic, and mood stabilizer therapy in patients with treatment-resistant or suboptimal response to psychotropic medications.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}